Depletion of CD20+ B cells has been related to reduced clinical activity in relapsing–
remitting multiple sclerosis. The underlying mechanism is not understood, because serum …

CD20-positive B-cell depletion is a highly promising treatment for multiple sclerosis (MS),
but the mechanisms underlying therapeutic effects are poorly understood. B cells are …

Background Multiple sclerosis (MS) is often considered to be a CD4, T cell-mediated
disease. This is largely based on the capacity of CD4 T cells to induce relapsing …

This study investigated the effect of CD20-positive B-cell depletion on central nervous
system (CNS) white and gray matter pathology in experimental autoimmune …

Objective Clinical studies indicate that anti‐CD20 B‐cell depletion may be an effective
multiple sclerosis (MS) therapy. We investigated mechanisms of anti‐CD20‐mediated …

The contribution of autoantibody-producing plasma cells in multiple sclerosis (MS) remains
unclear. Anti-CD20 B cell depletion effectively reduces disease activity in MS patients, but it …

OBJECTIVE: Assess whether CD70+ B cells contribute to EAE. MATERIALS AND
METHODS: MOG-specific TCR transgenic mice (2D2) were crossed with mice with …

Background Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous
system (CNS) for which several new treatment options were recently introduced. Among …

The anti-CD20 antibody ocrelizumab, approved for treatment of multiple sclerosis, leads to
rapid elimination of B cells from the blood. The extent of B cell depletion and kinetics of their …

The remarkable clinical efficacy of anti-CD20 monoclonal antibodies (mAb) in relapsing-
remitting multiple sclerosis points at the critical involvement of B cells in the disease …